Cidara Therapeutics Inc.
Cidara Therapeutics Announces Positive Topline Results for CD388 in Phase 2b Trial
Summary
Cidara Therapeutics, Inc. announced on June 23, 2025, positive topline results from its randomized, double-blind, placebo-controlled Phase 2b NAVIGATE trial for CD388, an influenza prevention treatment. The study met its primary endpoint and all secondary endpoints, demonstrating statistically significant prevention efficacy across different dose groups. CD388 was well-tolerated with no unexpected adverse events. The company plans to present further results at scientific conferences and has requested an end-of-Phase 2 meeting with the FDA.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement